CorMedix Q3 2021 Earnings Report

Reported a net loss due to increased costs related to DefenCath manufacturing.

Key Takeaways

CorMedix reported a net loss of $8.6 million, or $0.22 per share, for the third quarter of 2021, compared to a net loss of $6.6 million, or $0.22 per share, for the third quarter of 2020. The increased loss was attributed to higher costs related to the manufacturing of DefenCath.

Net loss was $8.6 million, or $0.22 per share, compared to a net loss of $6.6 million, or $0.22 per share, in Q3 2020.

Operating expenses increased by approximately 30% to $8.6 million.

R&D expense increased by approximately 62% to $4.7 million.

Total cash on hand and short-term investments as of September 30, 2021 was $72.0 million.

Previous year: -$0.22

+0.0%